当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2016年第27期 > 正文
编号:12947432
含替吉奥化疗方案治疗晚期食管癌的研究进展(4)
http://www.100md.com 2016年9月25日 《中国医药导报》2016年第27期
     [18] 杨凯,张伟杰,马会芳,等.紫杉醇联合替吉奥治疗晚期食管癌的临床疗效分析[J].河南医学研究,2015(1):28-30.

    [19] 商迪,尹胜杰,季洪波,等.紫杉醇联合替吉奥胶囊治疗晚期食管癌的临床疗效观察[J].中国医药指南,2015(2):34-35.

    [20] Nakamura T,Ota M,Narumiya K,et al. [Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer] [J]. Gan To Kagaku Ryoho,2012,39(2):227-230.

    [21] 葛伯建,高湘湘,顾寄树,等.替吉奥胶囊联合多西他赛治疗晚期食管癌临床疗效观察[J].实用临床医药杂志,2011,15(17):102-104.

    [22] Sandler AB,Kindler HL,Einhorn LH,et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction [J]. Ann Oncol,2000,11(9):1161-1164.

    [23] Chen Y,Perng R,Tsai C,et al. A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy [J]. Lung Cancer,2006,52(3):333-338.

    [24] Cho JY,Paik YH,Chang YS,et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma [J]. Cancer,2005,104(12):2753-2758.

    [25] 宋子琰,郑义同,卞宝祥.吉西他滨联合替吉奥治疗晚期食管癌的临床观察[J].肿瘤基础与临床,2011(4):293-295.

    (收稿日期:2016-05-20 本文编辑:赵鲁枫) (林炯 余忠华)
上一页1 2 3 4